Inactief instrument

Andere talen Active Biotech AB Xetra

Aandelen

BTPC

SE0001137985

slotkoers Xetra Andere beurzen
- ^EUR	-

03/04	Active Biotech AB (publ) kondigt de start aan van de inschrijving voor de klinische fase I-biodistributiestudie met Laquinimod oogdruppels	CI
08/02	Active Biotech AB (publ) rapporteert resultaten voor het vierde kwartaal eindigend op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Annual Report 2023 Active Biotech AB (publ)	22/04
Active Biotech announces start of enrollment to the clinical phase I biodistribution study with laquinimod eye drops	03/04
Active Biotech AB Announces Start of Enrollment to the Clinical Phase I Biodistribution Study with Laquinimod Eye Drops	03/04
Active Biotech Q4 2023 - Three Externally Funded Trials in 2024	09/02
Active Biotech Year End Report 2023	08/02
Active Biotech AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	08/02
Active Biotech AB Reports Earnings Results for the Full Year Ended December 31, 2023	08/02
Number of shares and votes in Active Biotech	29/12
Active Biotech provides update on the scheduled clinical program for 2024	22/12
Active Biotech AB Provides Update on the Scheduled Clinical Program for 2024	22/12
Positive preclinical tasquinimod data presented at ASH 2023 now available on Active Biotech’s website	14/12
Active Biotech Raises SEK44 Million via Rights Offering	06/12
Active Biotech announces outcome of the Company’s rights issue	06/12
Active Biotech Teams Up with US Research Group on Clinical Study of Laquinimod Eye Drops	06/12
Active Biotech enters into collaboration agreement for clinical ocular biodistribution study with laquinimod	05/12
Active Biotech's nomination committee appointed	01/12
Active Biotech AB Appoints Mats Arnhög and Petter Wingstrand to Nomination Committee	01/12
Lead Principal Investigator Rebekka Schneider-Kramann presents the clinical plan and positioning of tasquinimod in myelofibrosis	01/12
Management and members of the board of directors have subscribed for shares in Active Biotech’s ongoing rights issue	29/11
Active Biotech publishes prospectus	13/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Active Biotech AB Xetra

Aandelen

BTPC

SE0001137985

Andere talen

Filters